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Abstract
Schizophrenia may be conceptualised using a dimensional approach to examine trait-like expression such as
schizotypy within non-clinical populations to better understand pathophysiology. A candidate psychosis-risk
marker, the auditory mismatch negativity (MMN) is thought to index the functionality of glutamatergic NMDA
receptor mediated neurotransmission. Although the MMN is robustly reduced in patients with schizophrenia,
the association between MMN and schizotypy in the general population is under-investigated. Thirty-five
healthy participants completed the Schizotypal Personality Questionnaire (SPQ) and a multi-feature MMN
paradigm (standards 82%, 50 ms, 1000 Hz, 80 dB) with duration (100 ms), frequency (1200 Hz) and intensity
(90 dB) deviants (6% each). Spearman’s correlations were used to explore the association between
schizotypal personality traits and MMN amplitude. Few associations were identified between schizotypal traits
and MMN. Higher Suspiciousness subscale scores tended to be correlated with larger frequency MMN
amplitude. A median-split comparison of the sample on Suspiciousness scores showed larger MMN
(irrespective of deviant condition) in the High compared to the Low Suspiciousness group. The trend-level
association between MMN and Suspiciousness is in contrast to the robustly attenuated MMN amplitude
observed in schizophrenia. Reductions in MMN may reflect a schizophrenia-disease state, whereas nonclinical schizotypy may not be subserved by similar neuropathology.

Key words: Mismatch negativity; MMN; schizotypy; suspiciousness; schizophrenia; event-related potential;
ERP
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Highlights:
•

Investigating schizotypy within non-clinical populations may allow us to better understand the
pathophysiology of schizophrenia

•

MMN is robustly attenuated in patients with schizophrenia but has not been rigorously investigated in
relation to schizotypy

•

The current study did not find strong associations between MMN and schizotypy within a non-clinical
population of young adults, but MMN was tended to be larger with higher suspiciousness scores

•

This study raises questions regarding MMN as a marker of psychosis-risk in non-clinical populations
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1. Introduction
Schizophrenia is a psychiatric illness characterised by positive symptoms including hallucinations and
delusions, negative symptoms such as avolition and alogia, and disorganised symptoms including bizarre
behaviour and speech (APA, 2013). Whilst current antipsychotic treatments have moderate efficacy (Leucht et
al., 2009), up to one third of patients remain symptomatic (van Os and Kapur, 2009). The aetiology of
schizophrenia remains poorly understood, and the importance of moving from a categorical diagnosis to a
dimensional approach is increasingly advocated by researchers within this field (David, 2010; Ettinger et al.,
2014; Nelson et al., 2013).
One way in which this continuum might be understood is in terms of trait-like expressions of
schizophrenia that are also present in varying degrees in the general population (Ettinger et al., 2014; Johns
and van Os, 2001a). For example, schizotypy describes a cluster of personality traits which include unusual
perceptual experiences, odd beliefs or magical thinking, odd or eccentric behaviour, social anxiety and
isolation, constricted affect, suspiciousness and paranoia (Raine, 1991). Each of these is argued to map
broadly onto the positive, negative and disorganised dimensions of schizophrenia (Fonseca-Pedrero et al.,
2011; Nelson et al., 2013). Nelson et al. (2013) review competing models of schizotypy, including the quasidimensional approach which suggests that a small group of people, approximately 10% of the population
known as “schizotypes”, are vulnerable to schizophrenia (Lenzenweger, 2006; Meehl, 1990) and the fully
dimensional approach (Claridge and Beech, 1995; Rawlings et al., 2008) in which schizotypy is
conceptualised as existing along a continuum within the general population. The latter model is well supported
in the literature (Johns and van Os, 2001b; Van Os et al., 2009), and is consistent with models describing
continuity in clinical versus non-clinical symptoms of schizophrenia in the population (Linscott and Van Os,
2013; Linscott and Van Os, 2010). Neither model assumes that schizotypal traits are sufficient indicators of
psychosis-risk, but rather that schizotypal traits interact with other environmental and genetic factors to confer
risk (Nelson et al., 2013; Rawlings et al., 2008). Given the complexities of investigations into schizophrenia,
including medication history, lifestyle factors such as substance use and smoking, and disease chronicity,
research exploring schizotypy in the general population may provide information pertinent to the aetiology and
risk factors associated with psychotic disorders (Nelson et al., 2013).
While there is a plethora of evidence from genetic studies in particular supporting the existence of
schizotypy on a continuum with schizophrenia, increasing evidence also comes from neuropsychological and
neurobiological research (for comprehensive reviews see,Ettinger et al., 2014; Nelson et al., 2013). For
example, recent structural MRI work has indicated that high schizotypy is associated with reduced grey matter
in the frontal and temporal lobes (DeRosse et al., 2014), reduced grey matter volume in medial prefrontal,
orbitofrontal, and temporal cortical regions (Ettinger et al., 2012), and an aberrant neural prediction error
signal (Corlett and Fletcher, 2012). Patients with schizotypal personality disorder showed altered auditory
evoked potential N1, P2, N2 and P3 components intermediate between schizophrenia patients and healthy
controls (Trestman et al., 1996). Schizotypy traits in a non-clinical population have also been associated with
reduced P3 amplitude (Kimble et al., 2000), altered power within the electroencephalography (EEG) gamma
frequency band (Kornmayer et al., 2015), sleep spindle density (Lustenberger et al., 2014), altered neural
oscillations during a working memory task (Koychev et al., 2011), and impaired sensory gating as indicated by
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reduced P50 suppression (Croft et al., 2004; Croft et al., 2001; Evans et al., 2007). However, others have
found a less clear pattern of findings; for example, Lagioia et al. (2010) did not find an association between
default-mode activity and schizotypy in an adolescent sample. Modinos et al. (2010) also reported larger
regional volumes in the medial posterior cingulate cortex (PCC) and the precuneus in individuals with high
psychosis proneness as measured by the Community Assessment of Psychic Experiences (CAPE), which is
contrary to findings in patients.
Intriguingly, despite a large body of research investigating alterations to the mismatch negativity
(MMN) in patients with schizophrenia, a brain marker sensitive to N-methyl-D-aspartate (NMDA) receptor
function (for a review see, Todd et al., 2013), very few studies have investigated the association between
MMN alterations and schizotypy. MMN is a frontocentrally maximal event-related potential (ERP) component,
defined as the point of greatest deviance following infrequent auditory (or visual) stimuli termed deviants,
presented within a predictable pattern of frequent tones (or stimuli) (termed standard stimuli) (Kujala et al.,
2007; Näätänen, 1995). The ‘deviant’ may differ from the ‘standard’ on a number of possible perceptual
features including stimulus duration, frequency (pitch), intensity and location. The MMN is a component of the
ERP visible within a difference waveform, computed by subtracting the brain response to the standard
stimulus from the brain response elicited by the deviant (Picton et al., 2000), and is argued to reflect the
evaluation of new auditory sensory input against current models of the acoustic environment (Garrido et al.,
2009; Winkler, 2007). The two known generators of MMN, the superior temporal gyrus (STG) and inferior
frontal gyrus (IFG; see Michie et al., 2016 for a review) are represented as a sum by mastoid-referenced MMN
data recorded at frontal sites and may only be accurately dissociated with source localisation or computational
approaches such as direct causal modelling (Garrido et al., 2009). Research in patients with schizophrenia,
have consistently focused on MMN recorded at the frontocentral site electrode site ‘Fz’, noting robust
reductions (Umbricht and Krljes, 2005).
Robust reductions in MMN amplitude have been noted in patients with schizophrenia (Erickson et al.,
2015; Näätänen and Kahkonen, 2009; Umbricht and Krljes, 2005), as well as their first degree relatives
(Jessen et al., 2001; Michie et al., 2002; Sevik et al., 2011). These findings highlight the potential utility of
MMN as a candidate endophenotype for the disorder (for a review of MMN as a marker of conferring
vulnerability to schizophrenia, see Todd et al., 2013), although the evidence is mixed, (see, Bramon et al.,
2004; Magno et al., 2008) and alterations to MMN have been noted in other disorders (for a review see,
Näätänen et al., 2011). In patients, reductions in MMN have been linked with greater impairments in social
and cognitive function (Näätänen et al., 2011), however evidence for an association between MMN and
positive or negative symptoms of schizophrenia remains unclear (Todd et al., 2013; Umbricht and Krljes,
2005). MMN elicited by duration deviants (and to a lesser extent intensity deviants) has been linked in
particular with the prodromal phase of illness (Todd et al., 2008), and is reduced in individuals at ultra-high
risk of developing the disorder and patients with first episode psychosis (Atkinson et al., 2012; Bodatsch et al.,
2011; Hermens et al., 2010; Hsieh et al., 2012; Kaur et al., 2011; Nagai et al.; Perez et al., 2014; Shaikh et al.,
2012; Solis-Vivanco et al., 2014). Patients with chronic schizophrenia exhibit significant reductions in
frequency MMN, with group differences for duration deviants less apparent at the later stages of illness (Todd
et al., 2008). Grey matter loss in left and right Heschl’s gyrus has been linked with attenuated frequency
(Rasser et al., 2011; Salisbury et al., 2007) and duration MMN (Rasser et al., 2011) respectively in patients

Schizotypy and MMN

6

with schizophrenia. There is mounting evidence therefore that MMN may be sensitive to stage of illness in
schizophrenia (i.e. attenuated duration MMN with the early stages of illness and reductions in frequency MMN
with the later stages of illness) and indeed, that (duration) MMN deficits may identify at risk individuals who go
on to develop psychosis (Atkinson et al., 2012; Bodatsch et al., 2011; Higuchi et al., 2013; Jahshan et al.,
2012; Murphy et al., 2013; Perez et al., 2014). Therefore, MMN is argued to be of particular interest with
regard to future work targeting biomarkers of psychosis risk in vulnerable populations (Belger et al., 2012;
Bodatsch et al., 2013; Light and Naatanen, 2013; Todd et al., 2013).
This work is already underway in individuals with schizotypal personality disorder features (Hong et
al., 2012; Liu et al., 2007; Niznikiewicz et al., 2009), children at risk of developing schizophrenia (Bruggemann
et al., 2013; Schreiber et al., 1992) and chronic cannabis users (e.g., Greenwood et al., 2014). Reduced MMN
in a normative sample with high positive (schizotypal) symptom scores on the Personality Syndrome
Questionnaire was reported in an abstract (Baldeweg et al., 1999), although the type of MMN was not
reported. Fernandes and colleagues (1999) found no effect on frequency MMN amplitude of schizotypal
symptoms, family history of psychosis, or group classification based on Chapman scales, in a normative
sample. Although they did not measure MMN, Bates (2005) reported an association between auditory
imprecision and higher schizotypal scores (measured using the Schizotypal Personality Questionnaire; SPQ)
in a normative sample, reflecting reduced fidelity of primary sensory representations measured using a
choice-reaction time task. Surprisingly, however, MMN has not been specifically investigated with respect to
schizotypal personality traits in the general population as measured by the widely used SPQ, which has
robust psychometric properties (Raine, 1991).
Therefore, the aim of the current study was to explore whether higher scores on the SPQ in a nonclinical sample were associated with attenuated MMN amplitude, consistent with the status of MMN as a
biomarker for psychosis-proneness.

2. Methods
2.1 Participants
Participants were thirty-five undergraduate students (9 male, median 20.92 years of age, range: 18.8
to 37.6 years) from the University of Wollongong who were recruited via the School of Psychology’s research
participation scheme, as well as via flyers placed on noticeboards on the University campus and colleges.
Exclusion criteria included any recent or regular (> twice weekly for a period of 6 months) illicit substance use,
self-reported hearing impairments and neurological illness. In addition, all participants completed audiometric
testing; all participants had normal hearing at ≤25 dB for 1000 Hz or 1500 Hz tones. All participants provided
informed consent, and the study was approved by the Human Research Ethics Committee of the University of
Wollongong. Participants received either course credit or AUD$30 for their involvement in the study.
2.2 Experimental paradigm and procedure
Participants were familiarised with the study procedures before informed consent was obtained. A
short structured interview was administered to participants to assess hearing or visual impairments, recent or
regular substance use, and presence of any neurological or psychological disorder. Participants completed
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the full version of the Schizotypal Personality Questionnaire (SPQ, Raine, 1991), a 74 item measure of
schizotypy, taking participants approximately 10 minutes to complete. SPQ scores on the nine subscales were
calculated: Ideas of reference, Odd beliefs or magical thinking, Unusual perceptual experiences,
Suspiciousness, Social anxiety, No close friends, Constricted affect, Odd behaviour, and Odd speech. In
addition, dimensional SPQ scores were calculated in accordance with Raine et al. (1994). Specifically, the
Cognitive-Perceptual dimension, which maps closely onto the positive symptoms of schizophrenia, was
calculated based on the subscale scores for Ideas of reference, Odd beliefs or magical thinking, Unusual
perceptual experiences, and Suspiciousness. The Interpersonal dimension, which has been linked with
negative symptoms in schizophrenia, was comprised of the Social anxiety, No close friends and Constricted
affect subscales, and the Disorganised dimension, linking with a similar set of symptoms in patients, was
calculated using the Odd behaviour and Odd speech subscales.
In addition to the SPQ, participants completed the Beck Depression Inventory (BDI, Beck et al.,
1961), State Trait Anxiety Inventory I and II (STAI, Spielberger et al., 1983), the Community Assessment of
Psychic Experiences (CAPE, Stefanis et al., 2002) and the Oldfield Handedness Questionnaire (Oldfield,
1971) to assess symptoms of depression, anxiety, psychotic-like experiences and handedness, respectively
(see Table 1). All participants also completed the Rey Auditory Verbal Learning Test (RAVLT), a measure of
verbal learning and memory, before being fitted with recording electrodes. Participants completed an eye
movement calibration task (Croft and Barry, 2000), and were instructed to sit as still as possible and to
minimise blinking whilst completing a multifeature mismatch negativity paradigm (Greenwood et al., 2014)
prior to two other EEG tasks not reported here. For further information on the multifeature paradigm, please
see Supplement 1 and Greenwood et al. (2014).
2.3 Mismatch negativity quantification
For information on EEG data acquisition and processing, please see detailed methods in Supplement
1. MMN peak amplitude for each deviant condition was computed as the most negative peak within a 130-230
ms latency range for the duration condition, and 100-200 ms latency range for the frequency and intensity
conditions. Quantification of the MMN was restricted to Fz only, as this component is largest at this site
(Duncan et al., 2009), and attenuated MMN in patients with schizophrenia is most clearly observed at frontal
scalp sites (Umbricht and Krljes, 2005).
2.4 Data analysis
As the SPQ results were not normally distributed, Spearman’s correlations were used to explore the
association between MMN and SPQ scores (including total, subscale and dimensional measures). In light of
a trend level association between the Suspiciousness subscale and frequency MMN (see Figure 2 and
section 3.2), a subsequent exploratory analysis was conducted comparing participants with high versus low
Suspiciousness scores, divided using a median split.
Table 1 reports demographic, symptom and RAVLT performance measures for the High and Low
Suspiciousness groups. Mann Whitney-U tests were used to compare the groups on demographic (age,
gender), psychological (SPQ total and subscale scores, CAPE total frequency and distress, and subscale
scores, BDI, STAI-I and II scores) and neuropsychological (RAVLT total score from trials 1 to 5) measures.
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MMN amplitude and latency data were entered into separate 2 (Group: High and Low Suspiciousness) by 3
(Condition: Duration, Frequency and Intensity) repeated measures ANOVA. Bonferroni corrected post-hoc
tests were used to follow-up significant main effects and interactions.
3. Results
3.1 Schizotypy scores in a non-clinical sample of young adults
The median total SPQ score was 19 with a range of 0 to 56 (mean: 21.1, SD=14.95); 5 individuals
received a score of 41 or more, indicating they fell within the previously suggested cut-off for severe
proneness to schizotypal personality disorder (Raine, 1991). Table 1 reports the median and range for SPQ
subscale and dimension scores.
3.2 Is schizotypy associated with MMN in a non-clinical sample of young adults?
Mismatch negativity difference waveforms at Fz for duration, frequency and intensity conditions are
shown in Figure 1a and mastoid referenced grand mean ERP waveforms at Fz to the standard and deviant
stimuli in Figure 1b. Spearman’s correlations revealed no association between MMN amplitude in any
condition and either the SPQ total score (all p>0.52), or the majority of subscale scores: Ideas of reference (all
p>0.52), Social anxiety (all p>0.33), Odd beliefs or magical thinking (all p>0.23), Unusual perceptual
experiences (all p>0.21), Odd behaviour (all p>0.66), Odd speech (all p>0.35), Constricted affect (all p>0.25)
and No close friends (all p>0.13). There was however, a trend-level association between the Suspiciousness
subscale and frequency MMN amplitude (rs(35) = -.306, p=0.073), with a non-significant association for
duration (rs(35) = -.208, p=0.23) and intensity MMN (rs(35) = -.158, p=0.37 see Figure 2). No significant
associations between SPQ dimensions and MMN amplitude in any condition were identified (Cognitive and
Perceptual dimension: all p>0.14; Interpersonal dimension: all p>0.62; Disorganised dimension: all p>0.48).
In light of the trend-level association between Suspiciousness and MMN, we subsequently
categorised individuals as high or low on Suspiciousness using a median split on Suspiciousness subscale
scores, and conducted an exploratory between-groups analysis. The High and Low Suspiciousness groups
2

(n=18 and 17, respectively) did not differ significantly in age (Z=-0.50, p=0.64), gender (Χ =-0.83, p=0.77),
state anxiety (Z=-0.98, p=0.35), frequency or quantity of alcohol (frequency: Z=-0.64, p=0.54; quantity: Z=0.78, p=0.46) or tobacco use per month (frequency: Z=-1.29, p=0.23; quantity: Z=-1.57, p=0.15), nor
performance on the RAVLT (Z=-0.43, p=0.68). In addition to higher Suspiciousness subscale scores (Z=5.18, p<0.001), the High Suspiciousness group reported significantly higher levels of depression (Z=-2.36,
p=0.02) and trait anxiety (Z=-2.20, p=0.03), higher SPQ total (Z=-3.57, p<0.001) and most SPQ subscale
scores (Ideas of reference (Z=-1.84, p=0.007); Social anxiety (Z=-2.36, p=0.02); Unusual perceptual
experiences (Z=-3.15, p=0.002); Odd behaviour (Z=-2.52, p=0.14); No close friends (Z=-2.07, p=0.043); with a
trend level difference for Constricted affect (Z=-1.97, p=0.057), but no group difference for Odd speech (Z=1.27, p=0.22)). The High Suspiciousness group also exhibited higher SPQ dimension scores (CognitivePerceptual dimension, Z=-4.19, p<0.001; Interpersonal dimension, Z=-3.65, p<0.001; trend level difference for
Disorganised dimension; Z=-1.79, p=0.077). Consistent with higher SPQ scores, CAPE total frequency (Z=3.45, p=0.004) and distress scores (Z=-2.36, p=0.02) were increased in the High Suspiciousness group,
including higher frequency of positive symptoms (Z=-2.55, p=0.01). In addition, the High Suspiciousness
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group reported higher frequency of negative and depressive symptoms and higher levels of distress
associated with positive and depressive symptoms on the CAPE, however these group differences only
reached trend level (all p<0.10).
MMN difference waveforms at Fz for duration, frequency and intensity conditions for the High and
Low Suspiciousness groups are shown in Figure 1c and mastoid referenced grand mean ERP waveforms at
Fz to the standard and deviant stimuli in Figure 1d. Mean amplitude for standard ERPs over the latency
windows used for MMN peak detection did not differ significantly between the groups.
Although for MMN amplitude, Condition was not found to interact significantly with Group (F<1), a
main effect of Condition was observed (F(2,66)=12.40, p<0.001) indicating MMN amplitude was reduced in
the frequency compared to the duration (Freq MMN M: -2.90 µV, SD: 1.35 µV; Dur MMN M: -4.53 µV, SD:
2.21 µV; p<0.001) and intensity conditions (Freq MMN M: -2.90 µV, SD: 1.35 µV; Int MMN M: -4.07 µV, SD:
2.18 µV; p<0.01). A significant effect of Group revealed larger MMN amplitude, irrespective of deviant
condition, in the High compared to the Low Suspiciousness group (High M: -4.35 µV, SD: 2.02 µV; Low M: 3.29 µV, SD: 1.63 µV; F(1,33)=4.22, p=0.048).
There were no associations between MMN amplitude in any deviant condition and RAVLT
performance (all p>0.30) or CAPE scores (all p>0.09).

4. Discussion
The current paper represents the first study to explore a potential association between auditory MMN
and schizotypy in a non-clinical sample, in accord with a fully dimensional model of schizotypy and
schizophrenia (Linscott and Van Os, 2013; Linscott and Van Os, 2010). This study was motivated by the
increasing support in the literature for research into non-clinical schizotypy as a means of investigating the
aetiology of schizophrenia whilst circumventing many of the complexities associated with conducting research
in this population. Nevertheless, despite the robust reductions in MMN amplitude observed in patients with
schizophrenia (Umbricht and Krljes, 2005), the current study did not find strong evidence for an association
between schizotypy and the MMN. We did however, find a trend-level association between suspiciousness
and MMN, such that, contrary to expectation, higher levels of suspiciousness were associated with
increasingly larger MMN amplitude, and MMN was significantly larger (irrespective of deviant stimulus type) in
a High compared to Low Suspiciousness group.
A consistent relationship between reduced MMN amplitude in schizophrenia and positive, negative or
disorganised symptoms, has not been reported (for a discussion of this issue see (Todd et al., 2013) and
meta-analysis (Umbricht and Krljes, 2005)). Instead, smaller MMN has been associated with impairments in
global functioning (Kim et al., 2014; Light and Braff, 2005a, b; Rasser et al., 2011); an association that may be
mediated by changes in brain structure and function, including grey matter loss (Rasser et al., 2011). Given
that the current study comprised university students, it is likely that social and global functioning were in a
normal range and reasonably homogenous in this group. Although MMN has long been argued a candidate
endophenotype for schizophrenia, Todd et al. (2013) have reviewed existing evidence for this claim and note
that while small MMN is reliably reported in patients, evidence for a phenotypic association with schizophrenia
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(based on the definition of endophenotype by Gottsman and Gould (2003)) and its independence from state
and disease-process requires substantiative further study, best addressed by longitudinal work. Further,
despite evidence that duration MMN is smaller in at risk groups (for example, those meeting at risk mental
state (ARMS) criteria, Atkinson et al., 2012; Higuchi et al., 2013; Jahshan et al., 2012; Nagai et al.; Shaikh et
al., 2012) and may predict transition to psychosis (Bodatsch et al., 2011; Higuchi et al., 2013; Perez et al.,
2014; Shaikh et al., 2012), Todd et al. (2013) highlight that it is currently unknown whether the reductions in
MMN observed in the ARMS group reflect psychosis-risk or alternatively, may reflect the early stages of
disease progression. If schizotypy reflects one end of a continuum with schizophrenia as described by a fully
dimensional model, it follows that smaller MMN should be associated with increasing schizotypy traits in the
general population. The current data however, do not support this hypothesis. An alternative hypothesis is
that attenuated MMN amplitude may be more specifically related to the disease state of schizophrenia and not
to schizotypy scores (or this belief / personality trait structure per se) in non-clinical populations.
Although there is not a large body of electrophysiological studies pertinent to schizotypy, interestingly,
we are not the first study to report findings opposite to those observed in patients with schizophrenia.
Importantly, larger frontal MMN to frequency deviants was reported in patients with schizotypal personality
disorder, though not paranoid personality disorder (Liu et al., 2007). In contrast to Bates (2005) showing an
association between higher schizotypal scores and auditory imprecision in a normative sample, Liu et al.
(2007) showed that schizotypal patients had normal discrimination of auditory stimuli and suggested that their
findings might reflect difficulty in filtering irrelevant stimuli. The MMN has been argued to reflect the brain’s
capacity to ‘gate in’ novel or new information (Boutros and Belger, 1999; Gjini et al., 2010), so it seems more
likely that larger MMN amplitudes might reflect compensatory processes possibly related to difficulty filtering
relevant from irrelevant auditory stimuli. In a study of treatment-refractory schizophrenia, in conjunction with
atypical topography, larger frequency MMN amplitude was also observed in patients relative to controls
(Milovan et al., 2004), which in light of the component’s unusual topography may indeed reflect compensatory
processing. More recently, a visual component similar to the auditory MMN was also enhanced in high
compared to low scorers on the O-LIFE questionnaire (Mason and Claridge, 2006) which the authors also
argue might reflect compensatory processes due to deficient executive functioning (Fuggetta et al., 2015).
Whilst these data are inconsistent with otherwise widely reported reductions in MMN in patients with
schizophrenia (Erickson et al., 2015; Umbricht and Krljes, 2005), they highlight the complexity and
heterogeneity within ‘at risk’ samples, including schizotypy.
A further hypothesis is that larger MMN amplitudes in the high Suspiciousness group may reflect
heightened involuntary attention, possibility related to distractibility (Näätänen et al., 2012), aberrant salience
(eg., Kornmayer et al., 2015) and altered early perceptual processing (Sumich et al., 2014). There is some
evidence that higher levels of suspiciousness may be linked with aberrant perceptual processing in nonclinical populations, and this may lead to ambiguous stimuli being interpreted as threatening (Sumich et al.,
2014) and may be related to changes in grey matter volume in left Heschl gyrus, a possible generator of MMN
(Kasai et al., 2003). Suspiciousness has been associated with heightened neural response, N200, to
emotional stimuli, regardless of specific emotion content (Fisher et al., 2014). Further, previous research in
patients with (clinically diagnosed) schizotypal personality disorder exhibited altered auditory evoked
potentials, with N1, P2, N2 and P3 components at levels which were intermediate to patients with
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schizophrenia and healthy controls (Trestman et al., 1996). Whereas research examining the underlying brain
structures may facilitate interpretation of these electrophysiological findings, some neuroimaging studies have
noted further disparate findings. For example, structural neuroimaging studies have shown, in contrast to
schizophrenia patient data, that (non-clinical) subjects with high positive schizotypy had larger grey matter
regional volumes in the medial posterior cingulate cortex (PCC) and the precuneus (Modinos et al. (2010).
One possible interpretation put forward by the authors was that increased grey matter volume in young adults
with high schizotypy might reflect delayed synaptic pruning (Modinos et al., 2010), consistent with the idea
that schizophrenia may be associated with altered neural development during adolescence (Rapoport et al.,
2005). Previously, grey matter reductions in frontotemporal regions have been linked with MMN reduction in
patients with schizophrenia (Rasser et al., 2011). In light of the young median age of our sample (21 years)
and the proposed relationship between MMN and NMDA receptor function, it is possible that our findings may
reflect delayed brain maturational processes, similarly to what was reported by Modinos et al. (2010).
Nevertheless, the current data continue to raise questions regarding the extent to which neurobiological
alterations associated with schizophrenia are similarly observed in schizotypy.
There are a number of limitations to the current study: First the results of the current study are limited
by the small sample size, exploratory nature of our analyses, and overrepresentation of female compared to
male participants. As very little research has examined the association between MMN and schizotypy in nonclinical adults, there is significant scope for future research to build on this study. It will be important to
replicate the non-significant findings in a large community sample, as it is possible that unmeasured
‘resilience’ factors, such as social and global functioning, are over-represented in the current sample of
undergraduate students. Second, in this study we focused solely on the MMN as a marker of risk. These
results could be strengthened in future studies if other candidate neurobiological markers of psychosisproneness such as the P50 (Bramon et al., 2004; de Wilde et al., 2007) and P300 (Bramon et al., 2005) were
also collected. The latter, especially an analysis of P3a, might inform a possible increased involuntary
attention response in a schizotypy sample. Additionally, in the current study we re-referenced our ERP data to
the mastoids and focused our analysis on the frontocentral MMN component. Future research would benefit
from additional and separate analysis of the temporal generators of the MMN for which source localisation
procedures would be required. Third, consistent with the argument that biological markers of psychosis risk
likely reflect underlying genetic factors common across schizotypy and schizophrenia, while it is the
interaction of these with environmental factors that causes individuals to go on to develop schizophrenia,
including data about potential environmental factors and candidate genes with measures of MMN could help
to elucidate the relationship between MMN, schizotypy traits, and the pathophysiology of schizophrenia (eg.,
Baker et al., 2005). Finally, it is possible that the associations with Suspiciousness observed in the current
study and psychological symptom differences between the High and Low Suspiciousness group may not be
specific to Suspiciousness per se and instead reflect a more general psychosis-prone phenotype. This
limitation of the current study is worthy of further investigation with a larger number of measures, including
broader measures of psychosis-proneness eg., the O-LIFE scale (Mason and Claridge, 2006).
In summary, the current paper reflects an exploratory investigation of an association between MMN
and schizotypy in a sample of non-clinical young adults. We found a larger MMN in individuals with High
compared to Low Suspiciousness, a pattern which is in direct contrast to attenuated MMN observed in
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patients. This finding is consistent with larger frequency MMN reported in clinical sample of patients with
schizotypal personality disorder (Liu et al. 2007). Importantly, in our study larger MMN amplitudes were found
within a non-clinical sample of young adults with higher Suspiciousness scores, and irrespective of MMN
deviant type. Given the robust literature of decreased MMN in patients with schizophrenia these data warrant
replication, as they raise questions regarding the (i) validity of the MMN as a marker of susceptibility in nonclinical and low risk populations and (ii) the relationship between schizotypy scores in non-clinical populations
and risk for schizophrenia.
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Table 1. Participant demographic information, cognitive and psychological symptom measures
Whole sample
N
Age

Median

Low Suspiciousness

[Range]

N

Median

[18.75-37.55]

17

20.48

17

4M/13F

High Suspiciousness

[Range]

N

Median

[19.14-37.55]

18

20.96

18

5M/13F

[Range]

35

20.92

35

9M/26F

30

2.50

[0-30]

17

2.50

[0-30]

13

2.50

[0.4-30]

30

9.50

[0-165]

17

8.13

[0-42]

13

10.00

[1.4-165]

17

0.20

[0-30]

10

0.00

[0-30]

7

1.00

[0-30]

14

1.00

[0-450]

9

0.00

[0-450]

5

1.00

[1-270]

RAVLT total words trials I to V

35

59.00

[38-68]

17

59.00

[38-67]

18

59.00

[48-68]

BDI

35

4.00

[0-17]

17

2.00

[0-11]

18

5.00

[0-17]*

STAI state

34

32.50

[19-57]

16

29.00

[19-57]

18

32.50

[20-49]

STAI trait

35

39.00

[21-62]

17

35.00

[21-53]

18

45.50

[24-62]*

SPQ Total

35

19.00

[0-56]

17

12.00

[0-21]

18

30.20

[3-56]**

SPQ Ideas of reference

35

2.00

[0-8]

17

1.00

[0-4]

18

4.00

[0-8]**

Gender
Alcohol frequency
Alcohol quantity

a

b

Cigarette frequency
Cigarette quantity

a

b

[18.75-27.23]

SPQ Excessive social anxiety

35

3.00

[0-8]

17

2.00

[0-7]

18

5.00

[0-8]*

SPQ Odd beliefs or magical thinking

35

0.00

[0-5]

17

0.00

[0-5]

18

1.00

[0-5]

SPQ Unusual perceptual experiences

35

1.00

[0-9]

17

0.00

[0-3]

18

2.50

[0-9]*

SPQ Odd or eccentric behaviour

35

1.00

[0-7]

17

0.00

[0-4]

18

2.50

[0-7]*

†

SPQ No close friends

35

2.00

[0-7]

17

1.00

[0-5]

18

3.50

[0-7]*

SPQ Odd speech

35

4.00

[0-9]

17

3.00

[0-6]

18

4.00

[0-9]

SPQ Constricted affect

35

1.00

[0-7]

17

1.00

[0-4]

18

1.50

[0-7]*

35

2.00

[0-8]

17

0.00

[0-1]

18

4.00

[2-8]**

SPQ Suspiciousness
SPQ Cognitive-Perceptual dimension

c

35

6.00

[0-23]

17

2.00

[0-10]

18

14.20

[2-23]**

SPQ Interpersonal dimensions

35

9.00

[0-30]

17

5.00

[0-15]

18

14.00

[3-30]**

SPQ Disorganised dimension

35

4.00

[0-15]

17

4.00

[0-10]

18

6.50

[0-15]

†

CAPE Total frequency

35

63.00

[41-104]

17

59.00

[42-73]

18

68.00

[53-104]*

CAPE Total distress

35

28.00

[4-82]

17

23.00

[4-63]

18

36.00

[11-82]*
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†

CAPE Negative frequency

35

24.00

[14-41]

17

22.00

[14-30]

18

25.50

[18-41]

CAPE Negative distress

35

11.00

[1-31]

17

11.00

[0-31]

18

13.00

[6-31]

CAPE Positive frequency

35

25.00

[17-46]

17

24.00

[18-28]

18

29.50

[21-46]*

CAPE Positive distress

35

7.00

[1-34]

17

6.00

[1-15]

18

10.50

[1-34]

CAPE Depressive frequency

35

13.00

[6-17]

17

13.00

[7-16]

18

13.50

[10-17]

9.00

†

CAPE Depressive distress

35

8.00

[1-20]

17

7.00

[1-19]

18

21

†
†

[2-20]

Notes: Comparisons between participants with High and Low Suspiciousness; Ϯp<0.10,*p < 0.05, **p <0.01.
Data reported as median [range].
a
Alcohol / Cigarette frequency measured as number of days per month alcohol/cigarettes were consumed.
b
Alcohol / Cigarette quantity measured as number of standard drinks/cigarettes were consumed per month.
C
SPQ dimensions, Cognitive-Perceptual dimension (Ideas of reference + Magical thinking+ Unusual perceptual Experiences+ Suspiciousness); Interpersonal dimensions (Social anxiety + No close
friends + Constricted affect); Disorganised dimension (Odd behaviour + Odd speech)
RAVLT, Rey Auditory Verbal Learning Test; BDI, Beck Depression Inventory; STAI-I, State Anxiety Index State score; STAI-II, State Anxiety Index Trait score; SPQ, Schizotypal Personality
Questionnaire; CAPE, Community Assessment of Psychic Experiences.
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Intensity

(a)

(b)

(c)

(d)

Figure 1.(a) Mismatch negativity (MMN) waveforms at Fz displayed for Duration, Frequency and Intensity deviant conditions. (b) Mastoid reference
unsubtracted ERP waveforms at Fz to standard (grey) and deviant tones (black lines). (c) Mismatch negativity (MMN) waveforms at Fz displayed for each
condition for the High Suspiciousness group (black solid line) and the Low Suspiciousness group (dashed line). (d) Mastoid reference unsubtracted ERP
waveforms at Fz to standard (grey lines) and deviant tones (black lines) for the High Suspiciousness group (solid lines) and for the Low Suspiciousness group
(dashed lines). Amplitude is shown in µV on the y-axis and time in milliseconds along the x-axis.

Schizotypy and MMN

Duration MMN

Frequency MMN

Intensity MMN

Figure 2. Scatter plots showing association between MMN in the Duration (left), Frequency (middle) and Intensity (right) conditions, Suspiciousness scores
(top row) and SPQ total scores (bottom row).
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